Arcoma launches new X-ray system OMNERA 500A on the US market
Arcoma launches new X-ray system OMNERA 500A on the US market
Arcoma AB today launches the new X-ray system Omnera 500A on the American market. OMNERA 500A Includes New Intelligent Automation Features to Help Improve Workflow and Efficiency, Without Compromising on Patient Care.
The OMNERA 500A offers outstanding performance and intelligent automation with features that puts efficiency and patient safety first. The system has a new design and a new modern user interface with smart functions that simplify workflow and are designed to facilitate disinfection. The OMNERA 500A also has a completely new wall stand and an updated X-ray table that improves the patient and user experience.
The OMNERA 500A is launched through Arcoma's partner Canon Medical Systems USA at the annual meeting RSNA, which this year will be held virtual. The fair runs this week. To see the new system in Canon Medical Systems' virtual booth, visit their website: https://us.medical.canon/
“Today’s hospitals are challenged with productivity and workflow demands like never before, and it’s imperative that their x-ray systems are able to perform seamlessly so that they can focus on their patients,” said Jay Aboujaoude, managing director, X-Ray Business Unit, Canon Medical Systems USA, Inc. “The OMNERA 500A meets that need so that technologists can produce images with exceptional image quality, made possible with the unparalleled Canon CXDI detector technology that is at the heart of the system.”
“It feels very good to launch the OMNERA 500A that is desired by our partner and the market. We are convinced that the launch of the product will help us increase sales and customer satisfaction in the future. Canon Medical Systems USA has prepared a fantastic professional virtual booth with a big focus on the new product, which will be exciting to see during the week." says Linda Ungsten, product manager at Arcoma.
About Canon Medical Systems USA
Canon Medical Systems USA, Inc., headquartered in Tustin, Calif., markets, sells, distributes and services radiology and cardiovascular systems, including CT, MR, ultrasound, X-ray and interventional X-ray equipment. For more information, visit Canon Medical Systems’ website at https://us.medical.canon.
About Canon Medical Systems Corporation
Canon Medical offers a full range of diagnostic medical imaging solutions including CT, X-Ray, Ultrasound, Vascular and MR, as well as a full suite of Healthcare IT solutions, across the globe. In line with our continued Made for Life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features. For more information, visit the Canon Medical website: https://global.medical.canon.
OMNERA is a registered trademark of CANON MEDICAL SYSTEMS USA, INC. Made for Life is a trademark of Canon Medical Systems Corporation. CXDI is registered trademarks of Canon in the United States and may also be registered trademarks or trademarks in other countries.
Arcoma, with long experience in the industry, is a leading provider of integrated digital X-ray systems with high quality and advanced technology. Arcoma’s products offer the latest digital imaging technology combined with technically advanced moving positioning systems and ergonomic Scandinavian design. Arcoma offers the customers complete, configurable and functional digital x-ray systems. The company's products are sold through retailers as well as OEM customers and today there are over 3,500 of Arcoma’s X-ray systems installed worldwide. Arcoma is listed on Nasdaq First North. For more information about Arcoma, please visit www.arcoma.se
For more information, please contact:
Sanna Rydberg, Phone: +46 706 069548, E-mail: firstname.lastname@example.org
The information was submitted, through the CEO, for publication on December 1, 2020 at. 8.30 AM.
For more IR-related information and the possibility of pressrelease prenumeration, please visit our IR page: www.arcoma.se/about-us/investors/
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Telefónica Germany selects Opanga Networks Inc for RAN Optimization27.1.2021 00:25:28 CET | Press release
MUNICH, Germany, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Telefónica Germany GmbH & Co. OHG announced that it has selected Seattle based Opanga Networks, Inc as its RAN Optimization partner in Germany. “Mobile Network performance is under intensifying strain from the continual growth in data traffic,” said Jochen Bockfeld, Director Core & Network Services at Telefónica Germany. “RAN Optimization software, that can be deployed rapidly in the mobile core, is mission critical to our being able to provide the best-in-class mobile experience for our customers.” Opanga’s highly innovative software solutions are founded on advanced machine learning techniques that provide immediate benefit to mobile network customer experience. When Opanga’s software is deployed, the network runs much faster to sustain the best possible user experience. “We are very proud to call Telefónica Germany our customer,” said Ben Hadorn, Head of European Operations for Opanga Networks. “Telefónica Germany is a flagship oper
ClearPoint Neuro, Inc. Announces Expansion of Pre-Clinical and Translational Development Team to Support Gene and Stem Cell Therapy Partners26.1.2021 22:05:00 CET | Press release
IRVINE, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ernesto Salegio, PhD will join the Company as Vice President, Segment Leader Translational and Pre-Clinical Research as part of ClearPoint’s Biologics and Drug Delivery team on March 1, 2021. Dr. Salegio brings over 19 years of experience in translational neuroscience with direct pre-clinical central nervous system (CNS) expertise in the delivery of therapeutics to the brain and spinal cord, including over 16 years of gene therapy experience working with adeno-associated viral vectors (AAV). ClearPoint Neuro’s Biologics and Drug Delivery team was established in 2020 to provide turn-key medical device innovation, therapy delivery development and clinical services customized for both pharmaceutical and academic partners working on gene and stem cell therapies to the brain. This team also of
Cority Strengthens Position as a Leader in Green Quadrant for EHS Software26.1.2021 21:35:00 CET | Press release
Recognized by Independent Analyst Firm for its “integrated end-to-end EHSQ solutions platform,” Cority makes a major move up as a Leader, demonstrates unparalleled market momentum Toronto, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Cority, the global enterprise EHS software provider that empowers those who transform the way the world works, today announced it has been named a Leader in the 2021 Green Quadrant for EHS Software. This is the fourth consecutive year Cority has been recognized as a Leader in this benchmark report by independent research firm Verdantix. The Green Quadrant EHS Software 2021 provides a detailed fact-based comparison of the 22 most prominent EHS software vendors in the industry. Based on the proprietary Verdantix Green Quadrant methodology, Cority made a significant move up the Leaders’ quadrant, strengthening its position as a robust, integrated platform encompassing each functional area of EHS. Cority placed among the top two vendor scores for software Application Cap
Corline Biomedicals företrädesemission övertecknad med 342 procent26.1.2021 19:00:00 CET | Pressemelding
DETTA PRESSMEDDELANDE FÅR INTE OFFENTLIGGÖRAS, PUBLICERAS ELLER DISTRIBUERAS, DIREKT ELLER INDIREKT, I ELLER TILL AUSTRALIEN, HONKONG, JAPAN, KANADA, NYA ZEELAND, SINGAPORE, SYDAFRIKA, USA ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN ÅTGÄRD HELT ELLER DELVIS ÄR FÖREMÅL FÖR LEGALA RESTRIKTIONER. DETTA PRESSMEDDELANDE UTGÖR INTE ETT ERBJUDANDE ATT FÖRVÄRVA VÄRDEPAPPER I CORLINE BIOMEDICAL AB. SE ÄVEN AVSNITTET ”VIKTIG INFORMATION” NEDAN. Corline Biomedical AB (publ) (”Corline” eller ”Bolaget”) meddelar att Bolagets företrädesemission (”Företrädesemissionen”), i vilken teckningsperioden löpte ut den 22 januari 2021, har fulltecknats. Den slutliga sammanräkningen i Företrädesemissionen visar att 1 483 218 aktier, motsvarande cirka 97,84 procent av de erbjudna aktierna, tecknades med stöd av teckningsrätter. Återstående 32 683 aktier har tilldelats de som tecknat aktier utan stöd av teckningsrätter. Företrädesemissionen är således fulltecknad och tillför Corline cirka 15 MSEK före emissionskost
Exel Industries :First quarter 2020-2021 revenue : A promising first quarter: 19% growth26.1.2021 18:00:00 CET | Press release
PRESS RELEASE February 26, 2021 First quarter 2020-2021 revenue A promising first quarter: 19% growth Q1 revenue €m2019 ‐ 20202020 - 2021Change in valueChange in %ReportedReportedReported* like-for-likeReported* like-for-likeAgricultural Spraying5658.5+2.4+3.9+4.4%+6.9%Sugar Beet Harvesters1516.4+1.5+1.9+9.9%+13%Garden Watering and Spraying7.913.6+5.7+6+72.3%+76.1%Industrial Spraying40.554.1+13.6+4.4+33.4%+10.8%EXEL Industries Group119.4142.6+23.2+16.2+19.4%+13.5% *like‐for‐like = at constant foreign exchange rates and scope First quarter 2020‐2021 The new year began with first quarter (October - November - December) 2020-2021 revenue of €142.6 million, up €23.2m (+19.4%) on Q1 2019-2020. Like-for-like sales were €135.6 million, giving organic growth of 13.5%. The performance continues the recovery started Q4 last year. Note that growth was achieved against a Q1 2019-2020 comparison base when only China was confined due to COVID-19. All geographical areas sustained or grew sales, parti
Solutions 30 : REMARKABLE REVENUE GROWTH IN 202026.1.2021 18:00:00 CET | Press release
Growth of +20.3% during the 4th quarter of 2020+19.4% growth in 2020Excellent revenue momentum and profitable growth prospects confirmed for 2021 Solutions 30 SE, the European leader in solutions for new technologies, disclosed its annual revenue today at December 31, 2020. In millions of euros12 monthsQ420202019% change20202019% changeTotal814.7682.2+19.4%238.3198.1+20.3%From France522.1434.4+20.2%158.3125.7+26.0%From Benelux136.1125.9+8.1%36.036.8-2.2%From other countries156.5121.9+28.4%44.035.6+23.6% The figures are presented under IFRS. Revenue for the 4th quarter of 2019, presented in Lux-Gaap at the time of its initial publication, has been adjusted. As an introduction to this press release and in light of the current destabilization campaign against the group, Solutions 30 wishes to highlight three fundamental aspects of its business model: Solutions 30 is a fast-growing European group with a network of 12,000 technicians working throughout Europe to install digital equipment, s
PRESS RELEASE: NACON AND DAEDALIC ENTERTAINMENT ARE FORMING A FELLOWSHIP TO PUBLISH AND DISTRIBUTE THE HIGHLY-ANTICIPATED THE LORD OF THE RINGS: GOLLUM26.1.2021 17:45:00 CET | Press release
NACON AND DAEDALIC ENTERTAINMENT ARE FORMING A FELLOWSHIP TO PUBLISH AND DISTRIBUTE THE HIGHLY-ANTICIPATED THE LORD OF THE RINGS: GOLLUM Lesquin, 26 January 2021 - NACON and Daedalic Entertainment are pleased to announce that they have signed a co-publishing and distribution agreement for the game The Lord of the RingsTM: GollumTM. Developed for Xbox and PlayStation consoles, Nintendo Switch™ and PC, the game will be released in 2022. The two companies decided to join forces to ensure that the game will meet the expectations of fans of The Lord of the Rings and fully leverage the power of the new generation of consoles. The universe will be faithfully represented thanks to the partnership with Middle-earth Enterprises, the company that holds the adaptation rights to the novel series by J.R.R. Tolkien. As soon as it was announced in spring 2019, the game generated an enormous amount of attention amongst players and fans, and achieved a high profile through the first video showcase last